These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 27783255)

  • 1. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
    Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
    Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.
    Benamar M; Guessous F; Du K; Corbett P; Obeid J; Gioeli D; Slingluff CL; Abbas T
    EBioMedicine; 2016 Aug; 10():85-100. PubMed ID: 27333051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
    Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pevonedistat targeted therapy inhibits canine melanoma cell growth through induction of DNA re-replication and senescence.
    Wood EA; Lu Z; Jia S; Assumpção ALFV; Van Hesteren MA; Huelsmeyer MK; Vail DM; Pan X
    Vet Comp Oncol; 2020 Sep; 18(3):269-280. PubMed ID: 31665821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.
    Bhatia S; Pavlick AC; Boasberg P; Thompson JA; Mulligan G; Pickard MD; Faessel H; Dezube BJ; Hamid O
    Invest New Drugs; 2016 Aug; 34(4):439-49. PubMed ID: 27056178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma.
    Foster JH; Barbieri E; Zhang L; Scorsone KA; Moreno-Smith M; Zage P; Horton TM
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
    Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
    Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nedd8-Activating Enzyme Is a Druggable Host Dependency Factor of Human and Mouse Cytomegalovirus.
    Flores-Martínez YA; Le-Trilling VTK; Trilling M
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924.
    Liao H; Liu XJ; Blank JL; Bouck DC; Bernard H; Garcia K; Lightcap ES
    Mol Cell Proteomics; 2011 Nov; 10(11):M111.009183. PubMed ID: 21873567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.
    Blank JL; Liu XJ; Cosmopoulos K; Bouck DC; Garcia K; Bernard H; Tayber O; Hather G; Liu R; Narayanan U; Milhollen MA; Lightcap ES
    Cancer Res; 2013 Jan; 73(1):225-34. PubMed ID: 23100467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.
    Czuczman NM; Barth MJ; Gu J; Neppalli V; Mavis C; Frys SE; Hu Q; Liu S; Klener P; Vockova P; Czuczman MS; Hernandez-Ilizaliturri FJ
    Blood; 2016 Mar; 127(9):1128-37. PubMed ID: 26675347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of tumor angiogenesis by targeting the protein neddylation pathway.
    Yao WT; Wu JF; Yu GY; Wang R; Wang K; Li LH; Chen P; Jiang YN; Cheng H; Lee HW; Yu J; Qi H; Yu XJ; Wang P; Chu YW; Yang M; Hua ZC; Ying HQ; Hoffman RM; Jeong LS; Jia LJ
    Cell Death Dis; 2014 Feb; 5(2):e1059. PubMed ID: 24525735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nedd8-activating enzyme inhibitor MLN4924 (Pevonedistat), inhibits miR-1303 to suppress human breast cancer cell proliferation via targeting p27
    Chen Y; Du M; Yusuying S; Liu W; Tan Y; Xie P
    Exp Cell Res; 2020 Jul; 392(2):112038. PubMed ID: 32360865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRFAP1 plays a protective role in neddylation inhibitor MLN4924-mediated gastric cancer cell death.
    Hu L; Bai ZG; Ma XM; Bai N; Zhang ZT
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8273-8280. PubMed ID: 30556867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.
    Sarantopoulos J; Shapiro GI; Cohen RB; Clark JW; Kauh JS; Weiss GJ; Cleary JM; Mahalingam D; Pickard MD; Faessel HM; Berger AJ; Burke K; Mulligan G; Dezube BJ; Harvey RD
    Clin Cancer Res; 2016 Feb; 22(4):847-57. PubMed ID: 26423795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting neddylation pathway with MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis in renal cell carcinoma.
    Wang J; Wang S; Zhang W; Wang X; Liu X; Liu L; Li L; Liang Y; Yu J; Jeong LS; Jia L; Zhao H; Zhang Y
    Biochem Biophys Res Commun; 2017 Sep; 490(4):1183-1188. PubMed ID: 28669728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AKT inhibitor MK-2206 sensitizes breast cancer cells to MLN4924, a first-in-class NEDD8-activating enzyme (NAE) inhibitor.
    Chen X; Cui D; Bi Y; Shu J; Xiong X; Zhao Y
    Cell Cycle; 2018; 17(16):2069-2079. PubMed ID: 30198810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells.
    Xu GW; Toth JI; da Silva SR; Paiva SL; Lukkarila JL; Hurren R; Maclean N; Sukhai MA; Bhattacharjee RN; Goard CA; Medeiros B; Gunning PT; Dhe-Paganon S; Petroski MD; Schimmer AD
    PLoS One; 2014; 9(4):e93530. PubMed ID: 24691136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells.
    Wang Y; Luo Z; Pan Y; Wang W; Zhou X; Jeong LS; Chu Y; Liu J; Jia L
    Cancer Biol Ther; 2015; 16(3):420-9. PubMed ID: 25782162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overactivated neddylation pathway as a therapeutic target in lung cancer.
    Li L; Wang M; Yu G; Chen P; Li H; Wei D; Zhu J; Xie L; Jia H; Shi J; Li C; Yao W; Wang Y; Gao Q; Jeong LS; Lee HW; Yu J; Hu F; Mei J; Wang P; Chu Y; Qi H; Yang M; Dong Z; Sun Y; Hoffman RM; Jia L
    J Natl Cancer Inst; 2014 Jun; 106(6):dju083. PubMed ID: 24853380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.